Tamoxifen, a specific ER modulator, widely used in BC treatment, possess an anti-estrogenic effect, which in turn reduces the GLUT-1 expression by two-fold in BC cells (Figure 1A) [44]. The gene discussed is SLC2A1; the disease is breast cancer.